到2021年，全球估计有5700万人患有痴呆症，而新数据表明，带状疱疹疫苗可将痴呆风险降低20%。跨地区研究将这一效应量化为在七年内避免五分之一的新发痴呆诊断，显示出与老龄化相关疾病轨迹中的显著统计变化。

证据利用了65至80岁接种建议中的严格年龄分界，形成了大规模自然实验，并在澳大利亚、新西兰、威尔士和安大略的464,000名居民中得到一致结果。该趋势不仅指向痴呆和轻度认知下降发生人数减少，也显示在多个卫生系统中具有可重复性。

2025年1月发表的一项涉及3,800名70岁以上成年人的研究，基于包含炎症和DNA累积变化在内的七项指标构建健康老龄化评分，并发现既往接种者炎症更低且总评分更好。虽然机制和保护持续时间仍不确定，当前统计信号支持潜在的更广泛免疫获益，同时强调在向更年轻人群扩展建议前需要更多数据。

By 2021, an estimated 57 million people worldwide had dementia, and new data suggest shingles vaccination cuts dementia risk by 20%. Across regions, this effect is quantified as averting one in five new dementia diagnoses over seven years, indicating a substantial statistical shift in age-related disease trajectories.

The evidence exploits sharp age cutoffs in recommendations for ages 65 to 80, creating large natural experiments, and shows consistent results across Australia, New Zealand, Wales, and 464,000 residents in Ontario. The trend points not only to fewer cases of dementia and mild cognitive decline but also to reproducibility across multiple health systems.

A January 2025 study of 3,800 adults over age 70 used a healthy-ageing score built from seven measures, including inflammation and accumulated DNA changes, and found previously vaccinated participants had lower inflammation and better overall scores. Although mechanisms and effect duration remain uncertain, the current statistical signal supports possible broader immune benefits while underscoring the need for more data before extending recommendations to younger groups.

Source: Can the shingles vaccine slow ageing?

Subtitle: The evidence is surprisingly strong

Dateline: 2月 19, 2026 05:02 上午